ICFL 2019, Berlin - Program


Thursday, 27 June 2019

16:00 – 17:20

Welcome address

Opening session

Rifaat Safadi, Hadassah Hebrew University

Quentin Anstee, Newcastle University, UK


Keynote Lecture:

  • What is NAFLD - NASH and how it is defined

       Jean-Francois Dufour, University of Bern, Switzerland


Keynote Lecture:

  • Global Epidemiology & Outcomes of the NAFLD

       Zobair Younossi, Inova Fairfax Hospital, USA

​17:20 – 18:20

  • Should I be looking for NASH in my clinic? 

       PRO - Jerome Boursier, Angers University Hospital, France


       CON - Mark Walker, Newcastle University, UK

Open discussion and Vote

Networking Reception



Friday, 28 June 2019

08:00 – 08:45
Morning Networking
08:45 – 09:15


Arun Sanyal, Virginia Commonwealth University, USA

Keynote lecture: 

  • Biomarkers in NAFLD - If not a biopsy, what - and why

       Quentin Anstee, Newcastle University, UK

09:15 – 11:15






Session 1: What tools do we have to assess disease severity in NAFLD


Blood Tests


  • Routine blood tests and Simple Scores in NAFLD

       Salvatore Petta, University of Palermo, Italy

  • New Technologies: Metabolomics, Genomics & Collagen Biomarkers

       Detlef Schuppan, Institute of Translational Immunology, Germany

MRI and Ultrasound


  • How to use imaging to evaluate NASH in the clinic – practical approaches for use in the real world?

       Manuel Romero Gomez, Institute of Biomedicine of Seville, Spain

  • Ultrasound-based elastography techniques: TE, ARFI & SSI

       Laurent Castera, University of Paris-VII, France

  • MR-based assessment of inflammation and fibrosis

       Stefan Neubauer, Oxford University, UK


Panel Discussion

11:15 – 11:45Coffee break, Exhibition & Poster Viewing

11:45 – 13:00










Session 2: Screening - How should I evaluate NASH in my Clinic?  


  • Gastro/Hepatologist perspective  

       Lawrence Serfaty, University of Strsbourg, France

  • Diabetes perspective

       Gianluca Perseghin, University of Milano-Bicocca, Italy


Case presentation

Panel discussion 

13:00 – 14:00

Lunch, Exhibition & Poster Viewing

14:00 – 15:25










Session 3: Treating the Metabolic Syndrome in patients with NAFLD


  • Medical Therapy for T2DM

       Michael Roden, German Center of Diabetology, Germany

  • Medical Therapy for Dyslipidaemia

       Dirk Muller-Wieland, Aachen University Hospital, Germany


Case presentation


Panel discussion

15:25 – 15:55
Coffee Break, Exhibition & Poster Viewing

15:55 – 17:45








Session 4: Treating NAFLD in patients with the Metabolic Syndrome: Current Options


  • Dietary Management

       Shira Zelber Sagi, Tel Aviv Medical Center, and School of Public oooHealth, the University of Haifa, Israel

  • Alcohol in NAFLD: an oxymoron or an important cofactor?

       Philip Newsome, University of Birmingham, UK

  • Current available pharmacological therapeutic options for NAFLD using drugs available today

       Kris Kowdley, Swedish Medical Center, USA

  • Bariatric surgery for NAFLD

       Sebastian Mueller, University of Heidelberg, Germany


Case presentation


Panel discussion

17:45 – 19:15
Poster presentation & Reception


Saturday, 29 June 2019

08:00 – 08:30
Morning Networking

08:30 – 10:30




Session 5: Therapeutics Horizon Scanning: Treating NAFLD Tomorrow


Keynote Lecture:

  • NAFLD Pathophysiology: Targets for Novel Treatments

       Frank Tacke, Charité University, Berlin, Germany

Drug Targets in Phase 2/3 Trials – evidence base and status update


  • Bile acid signaling pathways (FXR/FGF19)  

       Michael Trauner, Medical University of Vienna, Austria

  • Metabolic Pathways: Insulin Signaling, PPARs, THRb 2

       Rifaat SafadiHadassah Hebrew University, Israel

  • Trials targeting fibrosis

       Jörn Schattenberg, University Medical Center Mainz, Germany


Panel Discussion

10:30 – 11:00
Coffee Break, Exhibition & Poster Viewing

11:00 – 12:30










Session 6: Drug development overview & Clinical Pharmacology in Practice


Keynote Lecture:

  • Why too many strategies are failing and do not continue?

       Arun Sanyal, Virginia Commonwealth University, USA

  • DILI in NAFLD: How to assess if a NASH drug is causing liver injury

       Guru Aithal, Nottingham University, UK


Panel discussion 

12:30 – 14:15
Lunch Break, Exhibition & Poster Viewing

14:15 – 16:00


Session 7: NAFLD & Malignancy


  • Mechanisms of obesity and NASH related carcinogenesis 

       Mathias Heikenwalder, German Cancer Research Center, Germany

  • HCC Surveillance in NAFLD – who, how and should you?

       Helen Reeves, Newcastle University, UK

  • Extra-hepatic malignancies in NAFLD

       Elisabetta Bugianessi, University of Turin, Italy


Case presentation

Panel discussion 

16:00 – 16:30
Summing up & Closing Remarks

Keep Me Updated

​​​ ​​​​​ ​​​​​ ​​​​​